Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Oncolytics Biotech Inc. - Common Shares (TSX:ONC)

0.7700 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.7700
Bid (Size) 0.7600 (5)
Ask (Size) 0.8500 (110)
Prev. Close 0.7700
Today's Range 0.7700 - 0.7700
52wk Range 0.6700 - 2.080
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer
Recent clinical data presentations in these two hard-to-treat GI cancers, coupled with strong efficacy signals in breast cancer, demonstrate the potential of pelareorep across very different tumor... 
Via FinancialNewsMedia
Optimism in War on Cancer on the Rise, as Biotech Companies Roll Out More Wins
Vancouver, BC – February 18, 2025 – USA News Group News Commentary – Despite optimism coming from the launch of Project Stargate (a $500 billion investment in AI data centers), there is still cause for... 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence

Performance

YTD
-41.7%
-41.7%
1 Month
-15.4%
-15.4%
3 Month
-34.7%
-34.7%
6 Month
-56.2%
-56.2%
1 Year
-47.3%
-47.3%

More News

Read More
Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium
Via FinancialNewsMedia
Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus
Via FinancialNewsMedia
Topics Death
Exposures Death
Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data
Via FinancialNewsMedia
Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus
From FN Media Group LLC
Via GlobeNewswire
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
Via FinancialNewsMedia
Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data
Via FinancialNewsMedia
Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
From FN Media Group LLC
Via GlobeNewswire
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
Via FinancialNewsMedia
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
From FN Media Group LLC
Via GlobeNewswire
Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium
Via FinancialNewsMedia
Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study
Via FinancialNewsMedia
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
Via FinancialNewsMedia
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
Via FinancialNewsMedia
Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer
Via FinancialNewsMedia
Exposures Product Safety
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
From FN Media Group LLC
Via GlobeNewswire
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
Via FinancialNewsMedia
Topics Death
Exposures Death
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
Via FinancialNewsMedia
Topics Death
Exposures Death
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
From FN Media Group LLC
Via GlobeNewswire
Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep’s Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action
Via FinancialNewsMedia
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
From FN Media Group LLC
Via GlobeNewswire
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
From FN Media Group LLC
Via GlobeNewswire

Frequently Asked Questions

Is Oncolytics Biotech Inc. - Common Shares publicly traded?
Yes, Oncolytics Biotech Inc. - Common Shares is publicly traded.
What exchange does Oncolytics Biotech Inc. - Common Shares trade on?
Oncolytics Biotech Inc. - Common Shares trades on the Toronto Stock Exchange
What is the ticker symbol for Oncolytics Biotech Inc. - Common Shares?
The ticker symbol for Oncolytics Biotech Inc. - Common Shares is ONC on the Toronto Stock Exchange
What is the current price of Oncolytics Biotech Inc. - Common Shares?
The current price of Oncolytics Biotech Inc. - Common Shares is 0.7700
When was Oncolytics Biotech Inc. - Common Shares last traded?
The last trade of Oncolytics Biotech Inc. - Common Shares was at 04/17/25 03:59 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.